FI4114826T3 - Farmaseuttisen yhdisteen kidemuotoja - Google Patents
Farmaseuttisen yhdisteen kidemuotoja Download PDFInfo
- Publication number
- FI4114826T3 FI4114826T3 FIEP21798287.5T FI21798287T FI4114826T3 FI 4114826 T3 FI4114826 T3 FI 4114826T3 FI 21798287 T FI21798287 T FI 21798287T FI 4114826 T3 FI4114826 T3 FI 4114826T3
- Authority
- FI
- Finland
- Prior art keywords
- crystal form
- disease
- pharmaceutical composition
- compound
- form according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 8
- 239000013078 crystal Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 208000025048 Action myoclonus-renal failure syndrome Diseases 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 150000002305 glucosylceramides Chemical class 0.000 claims 2
- 150000002339 glycosphingolipids Chemical class 0.000 claims 2
- 208000027025 progressive myoclonus epilepsy 4 Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000001905 GM2 Gangliosidoses Diseases 0.000 claims 1
- 208000009796 Gangliosidoses Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008955 Mucolipidoses Diseases 0.000 claims 1
- 206010072927 Mucolipidosis type I Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 claims 1
- 201000008977 glycoproteinosis Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000011985 sialidosis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
| PCT/EP2021/077100 WO2022069709A1 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4114826T3 true FI4114826T3 (fi) | 2023-11-21 |
Family
ID=72744696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21798287.5T FI4114826T3 (fi) | 2020-10-02 | 2021-10-01 | Farmaseuttisen yhdisteen kidemuotoja |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12116344B2 (enExample) |
| EP (3) | EP3978474A1 (enExample) |
| JP (2) | JP2023524169A (enExample) |
| KR (2) | KR20240056628A (enExample) |
| CN (1) | CN116390910A (enExample) |
| AU (2) | AU2021353055B2 (enExample) |
| BR (2) | BR112022018020B1 (enExample) |
| CA (1) | CA3193939C (enExample) |
| CL (1) | CL2023000943A1 (enExample) |
| DK (1) | DK4114826T3 (enExample) |
| ES (1) | ES2964105T3 (enExample) |
| FI (1) | FI4114826T3 (enExample) |
| IL (2) | IL301882B2 (enExample) |
| MA (1) | MA58885B1 (enExample) |
| MX (1) | MX2023003618A (enExample) |
| PE (1) | PE20240138A1 (enExample) |
| TW (1) | TW202229236A (enExample) |
| WO (1) | WO2022069709A1 (enExample) |
| ZA (1) | ZA202310184B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202337456A (zh) * | 2022-01-10 | 2023-10-01 | 荷蘭商雅捷法羅斯公司 | Ｇｍ２神經節苷脂症之治療 |
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| WO2025162745A1 (en) | 2024-02-01 | 2025-08-07 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4595964A1 (en) | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2687843T3 (es) | 2014-03-27 | 2018-10-29 | Academisch Medisch Centrum | Iminoazúcares N-(5-((aril o heteroril)metiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| EP3314009A2 (en) * | 2015-06-24 | 2018-05-02 | Universiteit Leiden | Glycosylated metabolites |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Pending
- 2021-10-01 IL IL301882A patent/IL301882B2/en unknown
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active Active
- 2021-10-01 US US18/029,842 patent/US12116344B2/en active Active
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 JP JP2022577645A patent/JP2023524169A/ja active Pending
- 2021-10-01 TW TW110136766A patent/TW202229236A/zh unknown
- 2021-10-01 IL IL316634A patent/IL316634A/en unknown
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en not_active Ceased
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
- 2024-08-30 US US18/821,921 patent/US20250059137A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4114826T3 (fi) | Farmaseuttisen yhdisteen kidemuotoja | |
| AU696620B2 (en) | Antipyretic and analgesic methods and compositions containing optically pure R-ketorolac | |
| JP2015514797A5 (enExample) | ||
| JP2016041701A5 (enExample) | ||
| UA96302C2 (en) | Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid | |
| RU2019134416A (ru) | Фармацевтические композиции | |
| CA1276154C (en) | Optically pure s-(-)-1-propyl-2,6-pipecoloxylidide hydrochloride monohydrate and a process for its preparation | |
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE | |
| HUP9801128A2 (hu) | Fukopeptidek, eljárás azok előállítására és alkalmazására, valamint ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
| WO2003024943A3 (en) | Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis | |
| RU2222538C2 (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и фармацевтическая композиция | |
| RU2017128880A (ru) | Производные (r)-2-метил-пиперазина в качестве модуляторов cxcr3 рецептора | |
| JP2006511482A (ja) | コリン作動性受容体を活性化できる化合物 | |
| BR0013265A (pt) | Composto, uso de um elemento estrutural, droga, preparação farmacêutica para uso oral ou parenteral, e, uso do composto | |
| US4073895A (en) | Isopropylamino pyrimidine orthophosphate | |
| IL43820A (en) | Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators | |
| RU2014140852A (ru) | Растительная композиция для лечения нарушений обмена веществ | |
| JP2005298425A (ja) | 抗ヒスタミン組成物、アレルギ性鼻炎の予防および治療用組成物、花粉症の予防および治療用組成物、じんま疹治療用組成物、抗ヒスタミン食品、抗ヒスタミン化粧料、抗ヒスタミン皮膚外用および抗ヒスタミン薬 | |
| JPWO2023051490A5 (enExample) | ||
| FR2673105B1 (fr) | Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections. | |
| CN104031032B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
| WO2001030736A3 (en) | Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors | |
| FR2278333A1 (fr) | Nouveaux composes diamino a substitution alkyle, procede pour leur preparation et preparations pharmaceutiques preparees a partir de ces composes | |
| BRPI0613751A2 (pt) | uso de um composto, sal ou solvato farmaceuticamente aceitável, um derivado farmaceuticamente funcional dos mesmos, composto ou um sal ou salvato farmaceuticamente aceitável, ou um derivado funcional do mesmo, formulação farmacêutica, método de tratamento de câncer, e, produto combinado | |
| Wu et al. | Resolution of Rac‐Bambuterol via Diastereoisomeric Salt Formation with o‐Chloromandelic Acid and Differences in the Enantiomers' Pharmacodynamical Effects in Guinea Pigs and Beagles |